<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="215075">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00285779</url>
  </required_header>
  <id_info>
    <org_study_id>20041132</org_study_id>
    <nct_id>NCT00285779</nct_id>
    <nct_alias>NCT00568581</nct_alias>
    <nct_alias>NCT00691106</nct_alias>
  </id_info>
  <brief_title>Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus</brief_title>
  <official_title>A Double-Blind, Randomized, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Etanercept 50mg SC Twice Weekly in the Treatment of Moderate to Severe Lichen Planus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wright State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tufts Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospitals Cleveland Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fivenson, David, M.D.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to assess the response of subjects to etanercept (as compared to placebo) in
      treating the physical signs of mucosal and cutaneous lichen planus. The investigators also
      wish to assess the effect of etanercept on disease-related itching, pain, and serious
      adverse events in patients with lichen planus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lichen planus affects up to 1% of the worldwide population. Recent estimates suggest
      approximately 0.44% of the US population suffers from this disease. Oral or genital
      involvement occurs in 60-70% of patients, and it may be the sole manifestation of disease in
      20-30% of patients.

      Lichen planus is a mucocutaneous disorder that can involve the skin, oral or genital mucosa,
      conjunctiva, and nails. On the skin, the disease presents as multiple papules, which can be
      localized or generalized, that are often extremely itchy. Mucosal disease can consist of
      either asymptomatic plaques or extremely painful erosive lesions. The disease course is
      unpredictable and typically lasts 1-2 years but can follow a chronic, relapsing course.
      Erosive mucosal disease is important to aggressively treat for many reasons: First, the
      associated pain can be debilitating for the patient. Patients with severe oral lichen planus
      can become malnourished due to pain associated with eating. Vulvar disease can cause
      dyspareunia, burning pain, and discharge; second, the disease tends to be chronic, with
      little chance for self-resolution; third, erosive disease is associated with an increased
      risk of squamous cell carcinoma in the affected areas. These cancers occur in up to 1% of
      patients over a 3-year period, and they can be aggressive and even-life threatening for the
      patient if not recognized and treated early.

      Several lines of evidence suggest that TNF-alpha plays a role in the pathogenesis of lichen
      planus. It has been shown that there are increased levels of TNF-alpha in the serum of these
      patients. In addition, skin and mucosal biopsies show increased TNF-alpha produced by the
      infiltrating lymphocytes as well as the basal keratinocytes. It has been suggested that the
      expression of TNF-alpha receptor on the basal keratinocytes may contribute to apoptosis.
      Also, TNFR1 (a TNF-alpha receptor) is expressed by the infiltrating mononuclear cells as
      well as the keratinocytes. Increased levels of soluble TNF receptors are also found in the
      serum of patients with lichen planus. A recent report also has shown that polymorphisms in
      the TNF-alpha gene are associated with both oral and cutaneous lichen planus. Finally,
      thalidomide, which partly functions as a potent inhibitor of TNF-alpha transcription, has
      been shown to be effective (in small case series and reports) in selected patients for the
      treatment of oral and genital lichen planus. However, thalidomide is a potent teratogen and
      cannot be used in women of childbearing potential. In addition, thalidomide usage not
      uncommonly results in neurotoxicity, which can be permanent, and thus limits use of this
      drug. Despite the evidence for a role of TNF-alpha in LP there are no reports of any TNF
      inhibitors being used for this disease.

      This is a double-blind, placebo-controlled pilot study to observe the safety and efficacy of
      etanercept in patients with lichen planus.

      This study will consist of 3 periods: first, a double-blind period (weeks 0-12) in which
      subjects will be randomized to etanercept 50 mg twice weekly or placebo; second, an
      open-label period (weeks 12-24) in which subjects who were randomized to placebo treatment,
      who have not achieved a complete remission, will be rolled over to use etanercept at 50 mg
      twice weekly. Subjects who previously received etanercept during weeks 0-12, who have not
      achieved a complete remission, will be continued on etanercept at a lower dosage of 25 mg
      twice weekly for weeks 12-24; third, an 8 week follow-up period for all subjects.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow recruitment
  </why_stopped>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Percentage of Patients Achieving a Response in Mucosal Disease (or Cutaneous Disease if no Mucosal Disease) at 12 Weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>This is a physician global assessment of disease (0=clear; 1=minimal disease; 2=mild disease; 3=moderate disease; 4=severe disease). The subject have a level &gt;=3 at baseline. To be considered a responder, the subject must achieve a level of 0 or 1, or, at least a 2 point improvement in the scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Patients Achieving a Response in Cutaneous or Mucosal Disease at 24 Weeks</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Physician Assessment of Surface Area of Disease, PSAD, (Mucosal Erosions and Cutaneous Disease) at 12 and 24 Weeks</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Individual and Total Cutaneous Target Lesion Scores at 12 and 24 Weeks</measure>
    <time_frame>12 weeks and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Assessment of Pain on a Visual Analogue Scale (VAS) at 12 and 24 Weeks</measure>
    <time_frame>12 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Assessment of Pruritus/Itching on a Visual Analogue Scale (VAS) at 12 and 24 Weeks</measure>
    <time_frame>12 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Assessment of Overall Disease Severity (Patient Global Assessment) at 12 and 24 Weeks</measure>
    <time_frame>12 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number and Percentage of Subjects Experiencing Serious Adverse Events (SAE) on Etanercept and Placebo</measure>
    <time_frame>12 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Placebo Patients Who do Not Have a Complete Response (Defined as a Physician Global Assessment of &quot;Clear&quot;) at 12 Weeks</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Placebo and Study-drug Patients Able to Discontinue Use of Topical Corticosteroids Through Week 24</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Lichen Planus</condition>
  <arm_group>
    <arm_group_label>Placebo injection</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patients receive normal saline injection twice weekly for weeks 1-12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Etanercept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients receive etanercept injection twice weekly for weeks 1-12.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etanercept</intervention_name>
    <description>etanercept 50 mg twice weekly for 12 weeks</description>
    <arm_group_label>Etanercept</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years old.

          -  Must carry a diagnosis of lichen planus as determined by biopsy

          -  Patients must have a score of 3 or greater on the physician global assessment (PGA).

          -  Patient must be considered appropriate for systemic therapy based upon fulfilling one
             of the following criteria:

               1. inability to maintain weight due to pain with eating, chewing, or swallowing;

               2. dyspareunia or dysuria due to genital lesions;

               3. itch/pain of sufficient severity that activities of daily living are
                  significantly affected

          -  Must be off systemic lichen planus treatment for 4 weeks prior to starting etanercept

          -  If using topical corticosteroid to the affected areas, the dose and frequency must be
             unchanged for 2 weeks prior to beginning the study agent and during the course of the
             study.

          -  Must be off topical cyclosporine, tacrolimus, or pimecrolimus for 2 weeks prior to
             starting the study drug and for the entire duration of the study.

          -  Must be able and willing to give written informed consent and comply with the
             requirements of the study protocol and must authorize release and use of protected
             health information.

          -  Women of childbearing potential must have a negative pregnancy test at the time of
             entry into the study and must be practicing successful contraception for at least 3
             months prior to the study.

          -  Subject or designee must have the ability to self-inject investigational product.

          -  Screening laboratory results are within the following parameters:

               -  Hemoglobin &gt; 10 g/dL

               -  White blood cells &gt; 3.5 x 10^9/L

               -  Neutrophils &gt; 1.5 x 10^9/L

               -  Platelets &gt; 100 x 10^9/L

               -  Lymphocytes &gt; 0.5 x 10^9/L

               -  Serum creatinine &lt; 1.5 mg/dL

               -  Hepatitis C serology - nonreactive

               -  AST and ALT &lt; 2X upper limit of normal (ULN)

        Exclusion Criteria:

          -  Subject is currently enrolled in another investigational device or drug trial(s), or
             subject has received investigational agent(s) within 90 days of baseline visit.

          -  Known HIV-positive status, any other immuno-suppressive disease, or inability to
             practice safe sex during the length of the study

          -  Subject has been diagnosed with a malignancy within the past 5 years

          -  Subject has signs or symptoms of a lymphoproliferative disease.

          -  Other skin or mucosal disease that might interfere with lichen planus assessments.

          -  Lichen planus variants including hypertrophic, atrophic, follicular (including lichen
             planopilaris), and bullous cutaneous forms.

          -  Patients with lichen sclerosis et atrophicus (LS&amp;A)

          -  Clinical history and lesion distribution suspicious for a lichenoid drug eruption

          -  Severe co-morbidities

          -  History of tuberculosis (TB) or positive PPD at screening. Known history of active
             hepatitis B or C, or lupus, SLE, history of multiple sclerosis or prior episode of
             central nervous system demyelination, transverse myelitis, optic neuritis, epilepsy,
             psychiatric condition, or other chronic serious medical illnesses.

          -  Subject has a diagnosis of congestive heart failure (CHF) of any severity

          -  Use of a live vaccine 90 days prior to, or during this study.

          -  Previous exposure and/or known sensitivity to etanercept

          -  Concurrent use, or failure of, any TNF-inhibitor

          -  Previous exposure to alefacept or efalizumab within 6 weeks of administration of
             study drug

          -  Concurrent sulfasalazine therapy

          -  Prior or concurrent cyclophosphamide therapy

          -  Active severe infections, or prior infection requiring hospitalization or
             oral/intravenous antibiotics within 4 weeks before screening visit, or between the
             screening and baseline visits.

          -  Active inflammatory bowel disease or peptic ulcer disease

          -  Drug or alcohol abuse within 12 months of screening visit.

          -  History of non-compliance with other therapies

          -  Pregnant or lactating

          -  Documented presence of any of the following:

               -  Proteinuria &gt; 1+ by dipstick screening

               -  24 Hour protein excretion &gt; 0.5 g

               -  Symptomatic liver disease with serum albumin &lt; 3 G/DL

               -  PT or PTT &gt; ULN, or

               -  Chronic liver disease

          -  Documented forced vital capacity &lt; 50% of predicted
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David F Fiorentino, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David F Fiorentino, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts - New England Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>David Fivenson, M.D. Dermatology, PLLC</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University School of Medicine</name>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <zip>26157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wright State University School of Medicine</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <lastchanged_date>February 16, 2015</lastchanged_date>
  <firstreceived_date>January 31, 2006</firstreceived_date>
  <firstreceived_results_date>January 28, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>David Fiorentino</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lichen Planus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This is a randomized, multi-center interventional trial in which patients were recruited at 11 sites in the United States (10 academic and one private practice). Enrollment was between June, 2006 and December, 2008. The first subject was enrolled in August, 2006 and the last patient was enrolled in November, 2008.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo Injection</title>
          <description>Placebo: Normal saline twice weekly for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Etanercept</title>
          <description>Etanercept: etanercept 50 mg twice weekly for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Placebo-controlled Period (wk 1-12)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Open Label Period (wk 12-24)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Follow-up Period (wk 24-32)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo Injection</title>
          <description>Placebo: Normal saline twice weekly for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Etanercept</title>
          <description>Etanercept: etanercept 50 mg twice weekly for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.4" spread="16.9"/>
                    <measurement group_id="B2" value="57.4" spread="16.0"/>
                    <measurement group_id="B3" value="53.7" spread="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Percentage of Patients Achieving a Response in Mucosal Disease (or Cutaneous Disease if no Mucosal Disease) at 12 Weeks</title>
        <description>This is a physician global assessment of disease (0=clear; 1=minimal disease; 2=mild disease; 3=moderate disease; 4=severe disease). The subject have a level &gt;=3 at baseline. To be considered a responder, the subject must achieve a level of 0 or 1, or, at least a 2 point improvement in the scale.</description>
        <time_frame>12 weeks</time_frame>
        <population>Intention to treat analysis (all participants received at least one dose of study drug). Missing data imputed using Last Observation Carried Forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Injection</title>
            <description>Placebo: Normal saline twice weekly for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Etanercept</title>
            <description>Etanercept: etanercept 50 mg twice weekly for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Patients Achieving a Response in Mucosal Disease (or Cutaneous Disease if no Mucosal Disease) at 12 Weeks</title>
          <description>This is a physician global assessment of disease (0=clear; 1=minimal disease; 2=mild disease; 3=moderate disease; 4=severe disease). The subject have a level &gt;=3 at baseline. To be considered a responder, the subject must achieve a level of 0 or 1, or, at least a 2 point improvement in the scale.</description>
          <population>Intention to treat analysis (all participants received at least one dose of study drug). Missing data imputed using Last Observation Carried Forward (LOCF).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0978</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of Patients Achieving a Response in Cutaneous or Mucosal Disease at 24 Weeks</title>
        <time_frame>24 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Physician Assessment of Surface Area of Disease, PSAD, (Mucosal Erosions and Cutaneous Disease) at 12 and 24 Weeks</title>
        <time_frame>24 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Individual and Total Cutaneous Target Lesion Scores at 12 and 24 Weeks</title>
        <time_frame>12 weeks and 24 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Assessment of Pain on a Visual Analogue Scale (VAS) at 12 and 24 Weeks</title>
        <time_frame>12 and 24 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Assessment of Pruritus/Itching on a Visual Analogue Scale (VAS) at 12 and 24 Weeks</title>
        <time_frame>12 and 24 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Assessment of Overall Disease Severity (Patient Global Assessment) at 12 and 24 Weeks</title>
        <time_frame>12 and 24 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number and Percentage of Subjects Experiencing Serious Adverse Events (SAE) on Etanercept and Placebo</title>
        <time_frame>12 and 24 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of Placebo Patients Who do Not Have a Complete Response (Defined as a Physician Global Assessment of &quot;Clear&quot;) at 12 Weeks</title>
        <time_frame>12 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of Placebo and Study-drug Patients Able to Discontinue Use of Topical Corticosteroids Through Week 24</title>
        <time_frame>24 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>This includes the entire 32 week timeframe of the trial. Thus, the placebo patients that cross over to etanercept from 12-24 weeks are also considered in the etanercept group during the 12-24 week timeframe. Also includes followup from 24-32 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo Injection</title>
          <description>Placebo: Normal saline twice weekly for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>Etanercept</title>
          <description>Etanercept: etanercept 50 mg twice weekly for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>Patient hospitalized for 3 days with chest congestion and fever and later found to have pneumonia.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oral pain with eating</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>sore throat</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Stomach cramps</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>gastric reflux</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergies</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Vaginal yeast infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Bacterial vaginosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>otitis media</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>oral candidiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Gout flare</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>worsening diffuse joint pains</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Knee arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Ankle and finger swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>increased back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Lightheadedness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Elevated creatinine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Chest congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Shortness of breath</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema at injection site</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Bruising at injection site</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>pruritis, generalized</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cataract surgery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Knee surgery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>facial flushing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Trial was terminated early due to low recruitment rates.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>David Fiorentino</name_or_title>
      <organization>Stanford University Department of Dermatology</organization>
      <phone>650-723-6316</phone>
      <email>fiorentino@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
